Cargando…

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients

Detalles Bibliográficos
Autores principales:	Jan, Muhammad Y., Sayegh, Skye E., Webb, Hanna T., Adebiyi, Oluwafisayo, Anderson, Melissa D., Mishler, Dennis P., Yaqub, Muhammad S., Taber, Tim, Sharfuddin, Asif A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233547/ https://www.ncbi.nlm.nih.gov/pubmed/34222731 http://dx.doi.org/10.1016/j.ekir.2021.06.012

Ejemplares similares

Nondirected Living Kidney Donation and Recipient Outcomes in the United States: A 20-Year Review
por: Jan, Muhammad Y., et al.
Publicado: (2022)

Vasopressin for Post-kidney Transplant Hypotension
por: Jan, Muhammad Y., et al.
Publicado: (2022)

A National Survey of Practice Patterns for Accepting Living Kidney Donors With Prior COVID-19
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Early Enterococcus-associated acute postinfectious glomerulonephritis after kidney transplant
por: Tandon, Teena, et al.
Publicado: (2014)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Epidemiology and Risk Factors for Invasive Fungal Infections in Pancreas Transplant in the Absence of Postoperative Antifungal Prophylaxis
por: Zachary, Jessica, et al.
Publicado: (2023)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
por: Arimura, Ken, et al.
Publicado: (2023)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19
por: Melton, James D., et al.
Publicado: (2021)

Efficacy of Casirivimab/Imdevimab in Kidney Transplant Recipients Admitted with Mild-to-Moderate COVID-19: A Case Series
por: Rajmane, Siddhavinayak Suryakant, et al.
Publicado: (2023)

Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
por: Pham, Danny H., et al.
Publicado: (2021)

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
por: Chen, Peter, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Liu, Esther C., et al.
Publicado: (2021)

Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients
por: Taber, David J., et al.
Publicado: (2018)

Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community
por: Iqbal, Leena, et al.
Publicado: (2021)

Bamlanivimab: Transfusion-related acute lung injury following off label use: case report
Publicado: (2021)

Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities
por: Walker, Victoria L., et al.
Publicado: (2022)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Sirolimus Conversion Efficacy for Graft Function Improvement and Histopathology in Renal Recipients with Mild to Moderate Renal Insufficiency
por: Joo, Dong Jin, et al.
Publicado: (2014)

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis
por: Zuo, Ling, et al.
Publicado: (2022)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study
por: Kumar, Rebecca N, et al.
Publicado: (2021)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59igv533o3k1b8f95act4kir25